65,437 trials
Non-small Cell Lung Cancer
Primary: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) — 35.8 percentage of participants
Epidermolysis Bullosa
Primary: Percentage of Participants With Event-free Survival — 67; 80; 50; 29 Percentage of participants
Diabetes · Pre-Diabetes
Primary: Water-soluble Cinnamon — 15; 11; 32; 32 Participants
Prostate Cancer
Primary: Sensitivity and Specificity of High Resolution Versus Standard MRI in Identifying Adverse Histology — 75; 71; 84; 54.8 percent
Covid19
Primary: Number of Participants Screened (Molecular) — 169; 61 Participants
Glaucoma
Primary: Mean Percent Change From Baseline in Intraocular Pressure (IOP) at Week 12 — -21.2; -15.7; -16.9; -18.5 percent change
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52) — -1.5; -1.9; -2.1 Percentage point of HbA1c — p=0.0006
Osteoarthritis · Overweight and Obesity
Primary: Dietary Intake — 2.1; 4.7; 0.8; 2.0 score on a scale
Thyroid Cancer · Thyroid Nodule · Benign Thyroid Nodule
Primary: Treatment Choice — 54; 51; 6; 7 Participants — p=0.720
Primary Mitochondrial Myopathy
Primary: Change in Distance Walked During a 12 Minute Walk Test — 26.75; 30.89 meters
Pain
Primary: Visual Analog Scale (VAS) Score — 24.77; 25.02; 25.19; 23.64 score on a scale — p=.37
Malignant Glioma · Glioblastoma Multiforme · Anaplastic Astrocytoma
Primary: Number of Participants With Treatment Related Adverse Events — 21 Participants
Anxiety Disorders
Primary: Pediatric Anxiety Rating Scale — 13.596491; 14.557377; 11.50; 12.206897 units on a scale
Prostatic Neoplasm
Primary: Urinary Function Scores — 80.1; 81.4 Scores on a scale (0-100)
Essential Thrombocythemia
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 73 Participants